Cranial nerve V, VII, IX, X, and occipital nerves (CN V, VII, IX, X, ON)

The grouping of Cranial Nerves V (Trigeminal), VII (Facial), IX (Glossopharyngeal), X (Vagus), and the Occipital Nerves refers to a set of anatomical structures rather than a single molecular target. These nerves are collectively involved in the sensory, motor, and autonomic functions of the head and neck, and they play critical roles in the pathophysiology of various pain syndromes [StatPearls: Neuroanatomy, Cranial Nerve 5, 7, 9, 10]. The Trigeminal nerve (CN V) is the primary mediator of the trigeminovascular system in migraine, while the Vagus nerve (CN X) is a key target for neuromodulation in epilepsy and cluster headache [StatPearls: Neuroanatomy, Cranial Nerve 5, 10]. In clinical practice, these nerves are targeted by therapeutic interventions such as OnabotulinumtoxinA injections, nerve blocks, and electrical stimulation to modulate nociceptive signaling [Blumenfeld et al., 2010, Headache; StatPearls: Neuroanatomy, Occipital Nerve]. For instance, the PREEMPT protocol for chronic migraine involves injections near the peripheral branches of CN V, CN VII, and the occipital nerves to inhibit the release of pro-inflammatory neuropeptides like CGRP [Blumenfeld et al., 2010, Headache]. Local anesthetics like lidocaine are used to block voltage-gated sodium channels in these nerves to treat conditions such as trigeminal or occipital neuralgia [StatPearls: Neuroanatomy, Occipital Nerve]. Because this entry describes multiple distinct anatomical structures, it is considered an incorrect designation for a specific molecular therapeutic target.

Other names

Trigeminal nerveFacial nerveGlossopharyngeal nerveVagus nerveOccipital nervesCN VCN VIICN IXCN X

Inhibition of neurotransmitter release (e.g., acetylcholine, CGRP) at peripheral nerve terminals via SNAP-25 cleavage or blockade of voltage-gated sodium channels to inhibit action potential propagation [StatPearls: Neuroanatomy, Occipital Nerve; Blumenfeld et al., 2010, Headache].